Optiscan Imaging

Optiscan Imaging Equity Ratio

The Equity Ratio of Optiscan Imaging (OIL.AX) as of Oct 9, 2026 is 86.00 %. In the previous year, Equity Ratio was 73.06 % — a change of 17.70% (higher).

Equity Ratio

86.00 %

YoY

17.70%

Last updated:

Equity Ratio of Optiscan Imaging is 2026 86.00 % . Equity Ratio of Optiscan Imaging was 2025 73.06 % . It decreases by 17.70% higher compared to the previous year.

The Optiscan Imaging Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
77.48 AUD
Jan 1, 2020
44.95 AUD
Jan 1, 2021
87.35 AUD
Jan 1, 2022
82.57 AUD
Jan 1, 2023
65.16 AUD
Jan 1, 2024
88.72 AUD
Jan 1, 2025
73.06 AUD
Jan 1, 2026
86.00 AUD
The Optiscan Imaging Equity Ratio history
YEAREquity RatioYoY
86.00 %+17.70%
73.06 %-17.65%
88.72 %+36.15%
65.16 %-21.08%
82.57 %-5.47%
87.35 %+94.35%
44.95 %-41.99%
77.48 %-0.04%
77.51 %+24.12%
62.45 %-251.69%
-41.17 %+139.26%
-17.21 %-23.93%
-22.62 %—
Access this data via the Eulerpool API

Optiscan Imaging Stock analysis

What does Optiscan Imaging do? Optiscan Imaging Ltd is an Australian company specializing in the development and commercialization of advanced imaging technologies. The company was founded in 1994 and is headquartered in Notting Hill, a suburb of Melbourne. Optiscan was originally established as a spin-off company from Monash University to enable the commercial application of a groundbreaking technology called confocal microscopy. However, over the years, the company has expanded into other imaging technologies and now offers a wide range of products and services. Optiscan's business model involves developing and bringing to market innovative technologies that can be used in biomedical research and clinical diagnostics. The company works closely with research institutions and companies in various industries to develop customized imaging solutions. Optiscan offers a wide range of products, including confocal microscopes, multiphotonic microscopes, real-time imaging systems, and Raman spectrometers. These products are used in various application areas such as cancer research, neurobiology, cell biology, and materials science. Another important area for Optiscan is veterinary imaging. The company has developed a product line for veterinary medicine that is used by veterinarians and researchers around the world. Optiscan's imaging systems enable veterinarians to obtain precise and detailed images of animals to enable better diagnosis and treatment. Optiscan also operates a service department that offers customized imaging solutions to customers. The company provides services such as image processing, data analysis, and prototype development. Overall, Optiscan has become one of the leading providers of imaging technologies in Australia and globally over the past decades. The company has a long history of collaboration with leading research institutions and companies worldwide and remains committed to developing innovative solutions for the challenges of biomedicine and imaging. Optiscan Imaging is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Optiscan Imaging stock

Equity Ratio of Optiscan Imaging is 86.00 % in 2026.

Equity Ratio of Optiscan Imaging changed from 73.06 % to 86.00 %, representing a 17.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Optiscan Imaging since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Optiscan Imaging with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Optiscan Imaging

All Key Metrics — Optiscan Imaging